Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-week Randomized, Double-Blind, Parallel-Group, Multicenter Study to Demonstrate the Efficacy and Safety of Two Different Rosiglitazone Dosing Regimens, 4mg OD and 8mg OD, in Poorly-Controlled Drug Naive Patients With Type 2 Diabetes Mellitus

NCT00044460 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00044460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00044460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-week Randomized, Double-Blind, Parallel-Group, Multicenter Study to Demonstrate the Efficacy and Safety of Two Different Rosiglitazone Dosing Regimens, 4mg OD and 8mg OD, in Poorly-Controlled Drug Naive Patients With Type 2 Diabetes Mellitus
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2002
Completion date
April 10, 2003
Enrollment
142
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2